CEO, Averigon Consulting
Steve EngleSteve Engle has more than 20 years of leadership experience in the biotechnology, drug delivery and device industries. He is CEO of Averigon Consulting, an advisory firm to the life science industry. Mr. Engle was Chairman and CEO of XOMA, a developer of monoclonal antibody therapeutics including XOMA 052, an anti-inflammatory antibody for non-infectious uveitis and other indications. He was Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA. Mr. Engle served as VP of Marketing for Cygnus, a drug delivery company, where he helped gain approval of and launch Nicotrol for smoking cessation. He was VP of Marketing at a $50 million device company and a management consultant at Strategic Decisions Group and SRI International. Mr. Engle is a member of the Board of Directors of BayBio, former board member of BIO and former Chair of BIOCOM. He also served on the Board of the Lupus Foundation of America. Mr. Engle holds M.S.E.E. and B.S.E.E. degrees from the University of Texas in biomedical engineering.